Comparison · NCT00777179-57426874
Vandetanib vs Placebo: Disease of Response (DOR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib vs Placebo: Disease of Response (DOR). Trial comparisons, record NCT00777179-57426874. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00777179-57426874
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.44 | 0.333 | 0.553 | wilson | |
| Risk in group 2 | 0.405 | 0.27 | 0.555 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0352 | -0.149 | 0.21 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.09 | 0.695 | 1.7 | log | |
| Odds ratio, group 1 over group 2 | 1.16 | 0.537 | 2.49 | log | |
| Number needed to treat, for one more participant with the outcome on Vandetanib than on Placebo | 28.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib | Vandetanib 300 mg, orally, once daily | 33 | 75 | OG000 |
| Group 2 | Placebo | Matching Placebo | 17 | 42 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Disease of Response (DOR)
- Description
Number of patients showing Complete Response (CR), Partial Response (PR) or Stable Disease (SD) based on RECIST for the best response.~Number of patients showing Complete Response (CR, disappearance of all target lesions), Partial Response (PR, at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter) or Stable Disease (SD, Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum longest diameter since the treatment started) based on RECIST Criteria Version 1.0 (assessed by CT and/or MRI) for the best response
- Time frame
- Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.
- Population
Source ClinicalTrials.gov
Trial
- Title
- Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy
- NCT number
- NCT00777179
- Phases
- PHASE2
- Conditions
- NSCLC
- Interventions
- Vandetanib, Placebo
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2011-07-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00777179?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00777179-57426874